Quels sont les principaux facteurs de risque du MPP+ ?
L'exposition à des pesticides et à des produits chimiques industriels augmente le risque.
Facteurs de risquePesticides
#2
L'âge est-il un facteur de risque pour le MPP+ ?
Oui, le risque d'effets néfastes du MPP+ augmente avec l'âge.
ÂgeRisque
#3
Les antécédents familiaux influencent-ils le risque ?
Oui, des antécédents familiaux de maladies neurodégénératives augmentent le risque.
Antécédents familiauxMaladies neurodégénératives
#4
Le sexe joue-t-il un rôle dans le risque de MPP+ ?
Oui, des études montrent que les hommes sont plus à risque que les femmes.
SexeRisque
#5
Le mode de vie influence-t-il le risque de MPP+ ?
Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque.
Mode de vieAlimentation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "1-Méthyl-4-phényl-pyridinium : Questions médicales les plus fréquentes",
"headline": "1-Méthyl-4-phényl-pyridinium : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les 1-Méthyl-4-phényl-pyridinium : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-14",
"dateModified": "2025-03-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "1-Méthyl-4-phényl-pyridinium"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Composés de pyridinium",
"url": "https://questionsmedicales.fr/mesh/D011726",
"about": {
"@type": "MedicalCondition",
"name": "Composés de pyridinium",
"code": {
"@type": "MedicalCode",
"code": "D011726",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "1-Méthyl-4-phényl-pyridinium",
"alternateName": "1-Methyl-4-phenylpyridinium",
"code": {
"@type": "MedicalCode",
"code": "D015655",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Hemmige S Yathirajan",
"url": "https://questionsmedicales.fr/author/Hemmige%20S%20Yathirajan",
"affiliation": {
"@type": "Organization",
"name": "Department of Studies in Chemistry University of Mysore, Manasagangotri, Mysore-570 006, India."
}
},
{
"@type": "Person",
"name": "Yuka Yamamoto",
"url": "https://questionsmedicales.fr/author/Yuka%20Yamamoto",
"affiliation": {
"@type": "Organization",
"name": "Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. yuka@kms.ac.jp."
}
},
{
"@type": "Person",
"name": "Katsuya Mitamura",
"url": "https://questionsmedicales.fr/author/Katsuya%20Mitamura",
"affiliation": {
"@type": "Organization",
"name": "Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan."
}
},
{
"@type": "Person",
"name": "Jun Toyohara",
"url": "https://questionsmedicales.fr/author/Jun%20Toyohara",
"affiliation": {
"@type": "Organization",
"name": "Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Takashi Norikane",
"url": "https://questionsmedicales.fr/author/Takashi%20Norikane",
"affiliation": {
"@type": "Organization",
"name": "Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Fluoroscopic Intraoperative Breast Neoplasm and Node Detection.",
"datePublished": "2023-01-10",
"url": "https://questionsmedicales.fr/article/36728380",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/XCS.0000000000000548"
}
},
{
"@type": "ScholarlyArticle",
"name": "Metastatic primary breast neuroendocrine neoplasms: a case series.",
"datePublished": "2022-10-31",
"url": "https://questionsmedicales.fr/article/36314732",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/imj.15961"
}
},
{
"@type": "ScholarlyArticle",
"name": "Galectin-3 as a biomarker in breast neoplasms: Mechanisms and applications in patient care.",
"datePublished": "2022-09-20",
"url": "https://questionsmedicales.fr/article/36125083",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/JLB.5MR0822-673R"
}
},
{
"@type": "ScholarlyArticle",
"name": "The impact of Angiopoietin-2 genetic polymorphisms on susceptibility for malignant breast neoplasms.",
"datePublished": "2022-08-25",
"url": "https://questionsmedicales.fr/article/36008514",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-022-18712-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy.",
"datePublished": "2023-06-22",
"url": "https://questionsmedicales.fr/article/37473463",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejca.2023.112952"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétéromonocycliques",
"item": "https://questionsmedicales.fr/mesh/D006573"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pyridines",
"item": "https://questionsmedicales.fr/mesh/D011725"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composés de pyridinium",
"item": "https://questionsmedicales.fr/mesh/D011726"
},
{
"@type": "ListItem",
"position": 6,
"name": "1-Méthyl-4-phényl-pyridinium",
"item": "https://questionsmedicales.fr/mesh/D015655"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : 1-Méthyl-4-phényl-pyridinium - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur 1-Méthyl-4-phényl-pyridinium",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur 1-Méthyl-4-phényl-pyridinium",
"description": "Comment diagnostiquer l'exposition au MPP+ ?\nQuels examens sont recommandés pour le MPP+ ?\nQuels symptômes indiquent une intoxication au MPP+ ?\nLe MPP+ peut-il être détecté dans le sang ?\nQuels tests neurologiques sont utiles pour le MPP+ ?",
"url": "https://questionsmedicales.fr/mesh/D015655?mesh_terms=Breast+Neoplasms#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur 1-Méthyl-4-phényl-pyridinium",
"description": "Quels sont les symptômes principaux du MPP+ ?\nLe MPP+ cause-t-il des troubles cognitifs ?\nY a-t-il des symptômes non moteurs liés au MPP+ ?\nComment le MPP+ affecte-t-il le système nerveux ?\nLe MPP+ provoque-t-il des douleurs ?",
"url": "https://questionsmedicales.fr/mesh/D015655?mesh_terms=Breast+Neoplasms#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur 1-Méthyl-4-phényl-pyridinium",
"description": "Comment prévenir l'exposition au MPP+ ?\nY a-t-il des vaccins contre le MPP+ ?\nLes changements de mode de vie aident-ils à prévenir le MPP+ ?\nL'éducation sur le MPP+ est-elle importante ?\nLes contrôles réguliers sont-ils recommandés ?",
"url": "https://questionsmedicales.fr/mesh/D015655?mesh_terms=Breast+Neoplasms#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur 1-Méthyl-4-phényl-pyridinium",
"description": "Quels traitements sont efficaces contre le MPP+ ?\nLa réhabilitation est-elle utile pour les patients exposés au MPP+ ?\nPeut-on utiliser des antioxydants pour traiter le MPP+ ?\nLes thérapies complémentaires sont-elles bénéfiques ?\nLe traitement précoce du MPP+ est-il crucial ?",
"url": "https://questionsmedicales.fr/mesh/D015655?mesh_terms=Breast+Neoplasms#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur 1-Méthyl-4-phényl-pyridinium",
"description": "Quelles complications peuvent survenir avec le MPP+ ?\nLe MPP+ peut-il entraîner des chutes ?\nY a-t-il un risque accru de dépression avec le MPP+ ?\nLe MPP+ peut-il affecter la qualité de vie ?\nDes complications cardiovasculaires sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D015655?mesh_terms=Breast+Neoplasms#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur 1-Méthyl-4-phényl-pyridinium",
"description": "Quels sont les principaux facteurs de risque du MPP+ ?\nL'âge est-il un facteur de risque pour le MPP+ ?\nLes antécédents familiaux influencent-ils le risque ?\nLe sexe joue-t-il un rôle dans le risque de MPP+ ?\nLe mode de vie influence-t-il le risque de MPP+ ?",
"url": "https://questionsmedicales.fr/mesh/D015655?mesh_terms=Breast+Neoplasms#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'exposition au MPP+ ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biologiques et des évaluations neurologiques sont utilisés pour diagnostiquer l'exposition."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour le MPP+ ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM et l'électromyographie peuvent aider à évaluer les dommages neurologiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une intoxication au MPP+ ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tremblements, rigidité et bradykinésie peuvent indiquer une intoxication au MPP+."
}
},
{
"@type": "Question",
"name": "Le MPP+ peut-il être détecté dans le sang ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des analyses sanguines peuvent détecter la présence de MPP+."
}
},
{
"@type": "Question",
"name": "Quels tests neurologiques sont utiles pour le MPP+ ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de coordination et de réflexes peuvent évaluer l'impact neurologique du MPP+."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux du MPP+ ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent tremblements, rigidité musculaire et troubles de la marche."
}
},
{
"@type": "Question",
"name": "Le MPP+ cause-t-il des troubles cognitifs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition au MPP+ peut entraîner des troubles cognitifs et de la mémoire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes non moteurs liés au MPP+ ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la dépression et l'anxiété peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment le MPP+ affecte-t-il le système nerveux ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le MPP+ endommage les neurones dopaminergiques, entraînant des symptômes parkinsoniens."
}
},
{
"@type": "Question",
"name": "Le MPP+ provoque-t-il des douleurs ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs musculaires et articulaires peuvent être présentes chez les patients."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition au MPP+ ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les environnements contaminés et utiliser des équipements de protection."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins contre le MPP+ ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin spécifique contre le MPP+."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie aident-ils à prévenir le MPP+ ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire le risque de maladies neurodégénératives."
}
},
{
"@type": "Question",
"name": "L'éducation sur le MPP+ est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur les risques et les symptômes est essentielle pour la prévention."
}
},
{
"@type": "Question",
"name": "Les contrôles réguliers sont-ils recommandés ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers peuvent aider à détecter précocement les symptômes."
}
},
{
"@type": "Question",
"name": "Quels traitements sont efficaces contre le MPP+ ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments dopaminergiques et des thérapies physiques."
}
},
{
"@type": "Question",
"name": "La réhabilitation est-elle utile pour les patients exposés au MPP+ ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la réhabilitation aide à améliorer la mobilité et la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des antioxydants pour traiter le MPP+ ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antioxydants peuvent être envisagés pour réduire le stress oxydatif lié au MPP+."
}
},
{
"@type": "Question",
"name": "Les thérapies complémentaires sont-elles bénéfiques ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines thérapies complémentaires, comme l'acupuncture, peuvent soulager les symptômes."
}
},
{
"@type": "Question",
"name": "Le traitement précoce du MPP+ est-il crucial ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un traitement précoce peut ralentir la progression des symptômes parkinsoniens."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le MPP+ ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles moteurs sévères et des problèmes cognitifs."
}
},
{
"@type": "Question",
"name": "Le MPP+ peut-il entraîner des chutes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les troubles de la marche augmentent le risque de chutes chez les patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de dépression avec le MPP+ ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients exposés au MPP+ présentent un risque accru de dépression."
}
},
{
"@type": "Question",
"name": "Le MPP+ peut-il affecter la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes parkinsoniens peuvent significativement réduire la qualité de vie."
}
},
{
"@type": "Question",
"name": "Des complications cardiovasculaires sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études suggèrent un lien entre MPP+ et complications cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque du MPP+ ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exposition à des pesticides et à des produits chimiques industriels augmente le risque."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour le MPP+ ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'effets néfastes du MPP+ augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies neurodégénératives augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque de MPP+ ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études montrent que les hommes sont plus à risque que les femmes."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque de MPP+ ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque."
}
}
]
}
]
}
Preoperative localization is necessary for nonpalpable breast lesions. A novel procedure, fluoroscopic intraoperative neoplasm and node detection (FIND), obviates the preoperative painful and potentia...
This is an IRB-approved retrospective study (September 2016 to March 2021). Electronic chart review identified breast and axillary node procedures using wire localization (WL) or FIND. Primary outcome...
We identified 459 patients, of whom 116 (25.3%) underwent FIND and 343 (74.7%) WL. Of these, 68.1% of FIND and 72.0% of WL procedures were for malignant lesions. Final margin positivity was 5.1% (4 of...
FIND has lower positive margin rates and a trend towards lower re-excision rates compared with WL, proving its value in localizing nonpalpable breast lesions. It also offers accurate localization of a...
Breast neuroendocrine neoplasms represent a rare subtype of breast cancer which have not been well studied or characterised, particularly in the metastatic setting....
To present clinicopathological characteristics, treatment and outcomes of a series of patients with metastatic neuroendocrine carcinoma of the breast and review the current literature....
We performed a retrospective review to identify and describe patients with metastatic neuroendocrine carcinoma of the breast at our centre between 2011 and 2021. Medical records, pathology and imaging...
We present a series of seven female patients with metastatic neuroendocrine carcinoma of the breast, as defined by the World Health Organization classification, over a period of 10 years (2011-2021) f...
This series shows the use of multiple modalities in treating this disease, with different sequencing in different patients. Despite multiple modalities used in the first-line setting, first-line PFS r...
Galectin-3 is a member of the lectin family encoded by the LGALS3 gene on chromosome 14. It is secreted by a wide range of immune cells and mammary tumor cells. Through its activity on the tumor micro...
Breast cancer causes morbidity and mortality among women worldwide, despite much research illuminating the genetic basis of this disease. Anti-angiogenesis therapies have been widely studied, although...
Long-term complications are becoming more important as the survival rate of breast cancer improves. Treatment-related myeloid neoplasm is an important long-term complication in breast cancer survivors...
We evaluated the incidence and risk factors for the development of treatment-related acute myeloid leukaemia (AML)/myelodysplastic syndrome (MDS) in patients treated with early breast cancer....
We accessed the national Korean database to identify 153,565 patients diagnosed with breast cancer between January 2007 and October 2016 who underwent surgery for breast cancer. We estimated the cumul...
Of 153,575 patients, 79,321 received anthracycline-based adjuvant therapy, 14,317 received adjuvant therapy without anthracyclines and 46,657 did not receive adjuvant chemotherapy. Overall, 120 develo...
This study found that anthracycline-based adjuvant therapy significantly increased the risk of AML/MDS in Korean breast cancer patients, with the risk persisting for at least 10 years. While the cumul...
Neuroendocrine neoplasms (NENs) of the breast are rare and not well-studied. NEN are subcategorized as well-differentiated neuroendocrine tumor (NET) and poorly differentiated neuroendocrine carcinoma...
Between 2004 and 2015, 420 NET, 205 NEC, 146 Adenocarcinoma with NE differentiation (ACNED) and 1,479,520 of invasive carcinoma, not otherwise specified (IC-NOS) of the breast were identified in the N...
After adjusting for other prognostic factors, both NET and NEC of the breast showed significantly worse OS than IC-NOS (HR (95% CI) = 1.41 (1.17, 1.72), p = 0.005 and HR (95% CI) = 2.11 (1.67, 2.67), ...
NEN is a unique pathologic and clinical entity, which has worse clinical outcome compared to IC-NOS of the breast. Current therapeutics used in the treatment of IC-NOS improve, but do not fully mitiga...
Breast cancer is the most lethal malignancy for women worldwide. Developed countries, such as Portugal, Spain, and the United States, have declining mortality rates due to breast cancer; however, in d...
Data were obtained from the National Health System Department of Informatics (DATASUS), maintained by the Brazilian Ministry of Health, which includes the registers of hospitalization and mortality by...
From 2008 to 2019, 643,822 hospital admissions due to malignant neoplasm of breast were reported in Brazil, of which the South and Southeast regions were the most prevalent. Higher hospitalization rat...
We have shown an increase in morbidity and mortality over time, which is dependent on patients' age and region. The results presented here may contribute to the ongoing discussion about the role and f...
To explore the differential diagnosis of benign and malignant papillary neoplasms on MRI with non-mass enhancement....
A total of 48 patients with surgically confirmed papillary neoplasms showing non-mass enhancement were included. Clinical findings, mammography and MRI features were retrospectively analyzed, and lesi...
Fifty-three papillary neoplasms were shown on MR images with non-mass enhancement, including 33 intraductal papilloma and 20 papillary carcinomas (9 intraductal papillary carcinoma, 6 solid papillary ...
Papillary carcinoma on MRI with non-mass enhancement mostly showed internal clustered ring enhancement, while papilloma mostly showed internal clumped enhancement; additional mammography is of limited...
Primary neuroendocrine neoplasms of the breast (Br-NENs) are rare. The classification has been updated in recent years making interpretation of the data published challenging. It is unclear whether ne...
The database for breast cancer patients treated between 2009 and 2022 at the Maria Sklodowska-Curie National Research Institute of Oncology Branch Krakow was explored to search for Br-NENs. Patients' ...
We included 22 females with Br-NEN without metastases at the time of diagnosis. The median age was 64 years (range: 28-88), Of the cases, 18 were hormone receptor positive, all were HER-2 negative, th...
Br-NENs represent a heterogenous group of diseases, lacking data from prospective studies or clinical trials. There are no established treatment standards tailored for Br-NENs. Our patients' cohort ex...
We aim to identify predictors of therapy-related myeloid neoplasms (t-MN) in patients with breast cancer (BC) and cytopenias to determine the timing of bone marrow biopsy (BMBx). Patients with BC and ...
